High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

Published

Journal Article

We have developed a high-throughput platform to detect the presence of HIV-1 and SIV-specific ADCC-mediating antibody responses. The assay is based on the hydrolysis of a cell-permeable fluorogenic peptide substrate containing a sequence recognized by the serine protease, Granzyme B (GzB). GzB is delivered into target cells by cytotoxic effector cells as a result of antigen (Ag)-specific Ab-Fcγ receptor interactions. Within the target cells, effector cell-derived GzB hydrolyzes the substrate, generating a fluorescent signal that allows individual target cells that have received a lethal hit to be identified by flow cytometry. Results are reported as the percentage of target cells with GzB activity (%GzB). Freshly isolated or cryopreserved PBMC and/or NK cells can be used as effector cells. CEM.NKR cells expressing the CCR5 co-receptor are used as a target cells following: (i) coating with recombinant envelope glycoprotein, (ii) infection with infectious molecular clones expressing the Env antigens of primary and lab adapted viruses, or (iii) chronic infection with a variant of HIV-1/IIIB, termed A1953. In addition, primary CD4(+) T cells infected with HIV-1 in vitro can also be used as targets. The assay is highly reproducible with a coefficient of variation of less than 25%. Target and effector cell populations, in the absence of serum/plasma, were used to calculate background (8.6 ± 2.3%). We determined that an initial dilution of 1:50 and 1:100 is required for testing of human and non-human primate samples, respectively. This assay allows for rapid quantification of HIV-1 or SIV-specific ADCC-mediating antibodies that develop in response to vaccination, or in the natural course of infection, thus providing researchers with a new methodology for investigating the role of ADCC-mediating antibodies as correlates of control or prevention of HIV-1 and SIV infection.

Full Text

Duke Authors

Cited Authors

  • Pollara, J; Hart, L; Brewer, F; Pickeral, J; Packard, BZ; Hoxie, JA; Komoriya, A; Ochsenbauer, C; Kappes, JC; Roederer, M; Huang, Y; Weinhold, KJ; Tomaras, GD; Haynes, BF; Montefiori, DC; Ferrari, G

Published Date

  • August 2011

Published In

Volume / Issue

  • 79 / 8

Start / End Page

  • 603 - 612

PubMed ID

  • 21735545

Pubmed Central ID

  • 21735545

Electronic International Standard Serial Number (EISSN)

  • 1552-4930

Digital Object Identifier (DOI)

  • 10.1002/cyto.a.21084

Language

  • eng

Conference Location

  • United States